Drug Profile

Candesartan cilexetil/hydrochlorothiazide - Takeda

Alternative Names: Atacand HCT; Atacand Plus; Blopress Plus; CoKenzen; ECARD HD; ECARD LD; Parapres Plus 32; Parapres Plus Forte; TCV-116C

Latest Information Update: 11 Jan 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Takeda
Developer AstraZeneca; Takeda
Class Antihypertensives; Benzimidazoles; Benzothiadiazines; Biphenyl compounds; Heart failure therapies; Tetrazoles
Mechanism of Action Angiotensin type 2 receptor antagonists; Diuretics

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

11 Jan 2021 Candesartan cilexetil licensed to Cheplapharm Arzneimittel in Angola, Argentina, Aruba, Australia, Bahamas, Bahrain, Bermuda, Barbados, Benin, Botswana, Brazil, Brunei Darussalam, Burkina Faso, Cameroon, Canada, Cayman Islands, Chile, Colombia, Congo, Costa Rica, Curaçao, Côte D'Ivoire, Djibouti, Dominican Republic, Ecuador, Egypt, El Salvador, Gabon, Georgia, Ghana, Guatemala, Guinea, Haiti, Honduras, Iraq, Jamaica, Jordan, Kenya, Republic of Korea, Kuwait, Lebanon, Libya, Madagascar, Malaysia, Mali, Mauritania, Mauritius, Mexico, Namibia, New Zealand, Nicaragua, Niger, Nigeria, Oman, Palestine, Panama, Peru, Qatar, Russian Federation, Saudi Arabia, Senegal, Singapore, South Africa, Sri Lanka, Sudan, Togo, Trinidad and Tobago, Tunisia, Turkey, Ukraine, United Arab Emirates, Uruguay and Yemen for marketing
30 Oct 2020 AstraZeneca announces of its decision to divest commercial rights to candesartan cilexetil to Cheplapharm Arzneimittel GmbH
24 Jul 2018 Cheplapharm Arzneimittel acquires commercial rights to candesartan cilexetil/hydrochlorothiazide for Hypertension in Europe

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com